Study of PF-08049820 Tablets for Adults with Moderate to Severe Atopic Dermatitis Evaluating Safety and Effectiveness

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a study medicine called PF-08049820 for treating atopic dermatitis AD, also known as eczema. This condition often causes severe itching and rashes on the skin. The study focuses on adults aged 18 to 64 who have moderate to severe AD confirmed at least six months prior and who do not currently have a suitable prescribed medicine for their condition. Participants in the study will take either PF-08049820 tablets or placebo tablets daily by mouth for 12 weeks during two stages of the trial. The placebo tablets look like the study medicine but do not contain any active drug. Clinic visits occur on Day 1, Weeks 1, 2, 4, 6, 8, and 12, with a follow-up visit at Week 16. At these visits, participants will have their health and skin condition evaluated, including blood and urine tests and questionnaires about their symptoms and quality of life. Throughout the study, researchers will compare the experiences of those receiving PF-08049820 with those receiving placebo to determine safety and effectiveness. They will measure changes in the severity of eczema using tools like the Eczema Area and Severity Index EASI and other assessments of itching and skin appearance. Safety will be monitored by tracking any adverse events and changes in laboratory tests. Total participation lasts about 16 weeks from the first dose through follow-up.

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema